Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.65 |
| ▸ | HTR2B | P41595 | 6/20 | 0.57 |
| ▸ | MAOB | P27338 | 5/20 | 0.57 |
| ▸ | HTR2A | P28223 | 4/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139467 | 1.00 | HTR2C (1.00) | HTR2CSLC6A4HTR2BMAOBHTR2A | |
| SCHEMBL14568843 | 1.00 | HTR2C (1.00) | HTR2CSLC6A4HTR2BMAOBHTR2A | |
| SCHEMBL4139470 | 1.00 | HTR2C (1.00) | HTR2CSLC6A4HTR2BMAOBHTR2A | |
| SCHEMBL13069787 | 0.82 | HTR2C (0.70) | HTR2CSLC6A4HTR2BMAOBHTR2A | |
| SCHEMBL13751890 | 0.82 | HTR2C (0.69) | HTR2CSLC6A4HTR2BMAOBHTR2A | |
| SCHEMBL13751895 | 0.82 | HTR2C (0.69) | HTR2CSLC6A4HTR2BMAOBHTR2A | |
| SCHEMBL13751894 | 0.82 | HTR2C (0.69) | HTR2CSLC6A4HTR2BMAOBHTR2A | |
| SCHEMBL14568253 | 0.81 | HTR2C (0.68) | HTR2CSLC6A4HTR2BMAOBHTR2A | |
| SCHEMBL22957768 | 0.81 | HTR2C (0.68) | HTR2CSLC6A4HTR2BHTR2ADRD2 | |
| SCHEMBL22957767 | 0.81 | HTR2C (0.68) | HTR2CSLC6A4HTR2BHTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943162-B2 | Osteoporosis; cardiovascular disorders; anticancer agents;incontinence | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040072829-A1 | Piperazinyltriazines as estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072829-A1 | Piperazinyltriazines as estrogen receptor modulators | GPER1, ESR2, ESR1 | HTR2C 548/4885SLC6A4 3674/4885HTR2B 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.